Who are Quetiapine and Topiramate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone, divalproex, quetiapine fumarate or valproate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/quetiapine-and-topiramate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Quetiapine and Topiramate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quetiapine and Topiramate (Quetiapine and Topiramate) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic + anticonvulsant mood stabilizer combination. Area: Psychiatry / Neurology.

marketed Atypical antipsychotic + anticonvulsant mood stabilizer combination D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Quetiapine and Topiramate (Quetiapine and Topiramate) — University of Cincinnati. This combination uses quetiapine's dopamine and serotonin antagonism for antipsychotic/mood effects alongside topiramate's sodium channel blockade and carbonic anhydrase inhibition for mood stabilization and anticonvulsant activity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Quetiapine and Topiramate TARGET	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Risperidone, divalproex	Risperidone, divalproex	Nathan Kline Institute for Psychiatric Research	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	Dopamine D2 receptor (risperidone); histone deacetylase / GABA pathway (divalproex)
quetiapine fumarate or valproate	quetiapine fumarate or valproate	AstraZeneca	phase 3	Atypical antipsychotic + anticonvulsant mood stabilizer combination	Dopamine receptors (D2), serotonin receptors (5-HT1A, 5-HT2A); GABA pathway, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic + anticonvulsant mood stabilizer combination class)

AstraZeneca · 1 drug in this class
Nathan Kline Institute for Psychiatric Research · 1 drug in this class
University of Cincinnati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Quetiapine and Topiramate — Competitive Intelligence Brief. https://druglandscape.com/ci/quetiapine-and-topiramate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab